Erika Uehara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erika Uehara has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Akira Ishiguro
Center for Postgraduate Education and Training, National Center for Child Health and Development, Tokyo, Japan
2 shared publications- Akira Ishiguro
Center for Postgraduate Education and Training, National Center for Child Health and Development, Tokyo, Japan
1 shared publication - Atsushi Hattori
Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
1 shared publication - Chie Nagata
Department of Obstetrics and Gynecology, The Jikei University School of Medicine , Tokyo 105-8461
1 shared publication Dongchon Kang
Department of Clinical Chemistry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
1 shared publicationHideshi Fujinaga
Division of Neonatology, National Center for Child Health and Development, Tokyo, Japan
1 shared publication
Latest Publications
- 12 July 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (7) , 827-836
Molecular and Clinical Features of Congenital Hypothyroidism Due to Multiple DUOX2 Variants
Background: DUOX2 is one of the major causative genes of congenital hypothyroidism (CH). Still, the mutation spectrum and clinical outcomes of biallelic DUOX2 variants are not fully understood. This study aimed to elucidate the molecular features and long-term clinical manifestations of CH caused by multiple pathogenic DUOX2 variants. Methods: A total of 255 patients with CH were screened for rare variants of 11 known causative genes. DUOX2 variants were classified according to their protein structure and residual activity. In vitro assays were performed for several variants of unknown functions. Clinical analyses were conducted for patients with multiple pathogenic variants of DUOX2 but not of other genes. Results: We identified 24 pathogenic variants of DUOX2 , together with two benign variants and seven variants of uncertain significance, in 63 patients. The pathogenic variants included three missense substitutions and one frameshift variant that have not yet been linked to CH. Twenty-one patients carried multiple pathogenic DUOX2 variants without any other pathogenic gene variants. Three of the 21 patients harbored homozygous variants. Family analysis, long-read amplicon sequencing, and haplotype phasing confirmed compound heterozygosity of the DUOX2 variants in 14 patients, whereas the allelic positions of the variants in the remaining four patients could not be determined. Of the 21 patients, 19 were treated with levothyroxine; their ages at drug withdrawal ranged from 9 months to 21.4 years. Three patients required retreatment after drug-free intervals of 6 months, 8 months, and 10 years. There were no differences in clinical severity among patients with DUOX2 amorphic/amorphic, amorphic/hypomorphic, and hypomorphic/hypomorphic variants. Conclusions: These results broaden the mutational spectrum of DUOX2 . Furthermore, our data imply that patients with multiple pathogenic DUOX2 variants typically exhibit transient CH without significant genotype–phenotype correlations. Most importantly, this study demonstrated for the first time that these patients are at risk of developing recurrent hypothyroidism after a long drug-free interval.
- 12 July 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (7) , 827-836
Molecular and Clinical Features of Congenital Hypothyroidism Due to Multiple DUOX2 Variants
Background: DUOX2 is one of the major causative genes of congenital hypothyroidism (CH). Still, the mutation spectrum and clinical outcomes of biallelic DUOX2 variants are not fully understood. This study aimed to elucidate the molecular features and long-term clinical manifestations of CH caused by multiple pathogenic DUOX2 variants. Methods: A total of 255 patients with CH were screened for rare variants of 11 known causative genes. DUOX2 variants were classified according to their protein structure and residual activity. In vitro assays were performed for several variants of unknown functions. Clinical analyses were conducted for patients with multiple pathogenic variants of DUOX2 but not of other genes. Results: We identified 24 pathogenic variants of DUOX2 , together with two benign variants and seven variants of uncertain significance, in 63 patients. The pathogenic variants included three missense substitutions and one frameshift variant that have not yet been linked to CH. Twenty-one patients carried multiple pathogenic DUOX2 variants without any other pathogenic gene variants. Three of the 21 patients harbored homozygous variants. Family analysis, long-read amplicon sequencing, and haplotype phasing confirmed compound heterozygosity of the DUOX2 variants in 14 patients, whereas the allelic positions of the variants in the remaining four patients could not be determined. Of the 21 patients, 19 were treated with levothyroxine; their ages at drug withdrawal ranged from 9 months to 21.4 years. Three patients required retreatment after drug-free intervals of 6 months, 8 months, and 10 years. There were no differences in clinical severity among patients with DUOX2 amorphic/amorphic, amorphic/hypomorphic, and hypomorphic/hypomorphic variants. Conclusions: These results broaden the mutational spectrum of DUOX2 . Furthermore, our data imply that patients with multiple pathogenic DUOX2 variants typically exhibit transient CH without significant genotype–phenotype correlations. Most importantly, this study demonstrated for the first time that these patients are at risk of developing recurrent hypothyroidism after a long drug-free interval.
- 1 September 2019
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 25 (9) , 738-741
Utility of follow-up blood cultures for Gram-negative rod bacteremia in children
- 1 September 2019
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 25 (9) , 738-741
Utility of follow-up blood cultures for Gram-negative rod bacteremia in children
- 21 August 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (10) , 918-922
Risk factors of long hospital stay for immunoglobulin A vasculitis: Single‐center study
Background: Immunoglobulin A (IgA) vasculitis is a common, systemic childhood disease that occasionally interferes with oral intake of food and necessitates hospitalization. In Japan, there are no reports on the length of hospitalization or factors related to long‐term hospitalization in children with IgA vasculitis. In this study, we investigated the factors related to long‐term hospitalization.Methods: We reviewed the medical records of children aged ≤15 years with IgA vasculitis who were admitted to the National Center for Child Health and Development (Tokyo, Japan) between March 2008 and April 2017. We reviewed their gender, age, previous episodes, digestive symptoms, fever, laboratory data, urine analysis, ultrasound, and use of glucocorticoid on admission day. We compared the long‐stay (≥10 days) group (L) and the short‐stay (≤9 days) group (S) on logistic regression analysis.Results: Of the 68 children included in the analysis, 34 were male, and the average age was 71.9 ± 26.4 months. The median period of hospitalization was 10.5 days (range, 0.5–75 days), and 36 children were allocated to group L. In the logistic regression model including age, gender, gastrointestinal (GI) bleeding, and use of glucocorticoid, male sex (OR: 4.2; 95%CI: 1.3–13.5) and GI bleeding (OR: 7.6; 95%CI: 1.4–41.5) were significantly associated with hospitalization ≥10 days.Conclusions: In children with IgA vasculitis, male patients and those with GI bleeding were more likely to have a hospital stay ≥10 days.
- 21 August 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (10) , 918-922
Risk factors of long hospital stay for immunoglobulin A vasculitis: Single‐center study
Background: Immunoglobulin A (IgA) vasculitis is a common, systemic childhood disease that occasionally interferes with oral intake of food and necessitates hospitalization. In Japan, there are no reports on the length of hospitalization or factors related to long‐term hospitalization in children with IgA vasculitis. In this study, we investigated the factors related to long‐term hospitalization.Methods: We reviewed the medical records of children aged ≤15 years with IgA vasculitis who were admitted to the National Center for Child Health and Development (Tokyo, Japan) between March 2008 and April 2017. We reviewed their gender, age, previous episodes, digestive symptoms, fever, laboratory data, urine analysis, ultrasound, and use of glucocorticoid on admission day. We compared the long‐stay (≥10 days) group (L) and the short‐stay (≤9 days) group (S) on logistic regression analysis.Results: Of the 68 children included in the analysis, 34 were male, and the average age was 71.9 ± 26.4 months. The median period of hospitalization was 10.5 days (range, 0.5–75 days), and 36 children were allocated to group L. In the logistic regression model including age, gender, gastrointestinal (GI) bleeding, and use of glucocorticoid, male sex (OR: 4.2; 95%CI: 1.3–13.5) and GI bleeding (OR: 7.6; 95%CI: 1.4–41.5) were significantly associated with hospitalization ≥10 days.Conclusions: In children with IgA vasculitis, male patients and those with GI bleeding were more likely to have a hospital stay ≥10 days.
- Open Access
- 9 April 2018
- Published by Georg Thieme Verlag KG in American Journal of Perinatology Reports
- Vol. 08 (02) , e68-e70
Slow Elevation in Protein C Activity without a PROC Mutation in a Neonate with Intracranial Hemorrhage
Severe protein C (PC) deficiency leads to purpura fulminans and stroke in newborns. However, the clinical impact of plasma PC activity on the development of neonatal cerebral disease remains elusive. We report a case of hemorrhagic stroke associated with neonatal asphyxia and severe PC deficiency. Plasma PC and protein S activity 7 days after birth was 12% and 43%, respectively. No PROC mutation was found. PC levels did not exceed 20% until 2 months of age, even in the absence of consumption coagulopathy or vitamin K deficiency. Neither thromboembolic nor hemorrhagic events occurred during the infusion of activated PC concentrate (twice weekly, up to 68 days after birth). The PC activity levels gradually increased to the standard value for age by 9 months of age. The present case showed that neonatal PC deficiency without a PROC mutation caused an intracranial hemorrhage before a slow increase in PC activity.
- 9 April 2018
- Published by Georg Thieme Verlag KG in American Journal of Perinatology Reports
- Vol. 08 (02) , e68-e70
Open AccessSlow Elevation in Protein C Activity without a PROC Mutation in a Neonate with Intracranial Hemorrhage
Severe protein C (PC) deficiency leads to purpura fulminans and stroke in newborns. However, the clinical impact of plasma PC activity on the development of neonatal cerebral disease remains elusive. We report a case of hemorrhagic stroke associated with neonatal asphyxia and severe PC deficiency. Plasma PC and protein S activity 7 days after birth was 12% and 43%, respectively. No PROC mutation was found. PC levels did not exceed 20% until 2 months of age, even in the absence of consumption coagulopathy or vitamin K deficiency. Neither thromboembolic nor hemorrhagic events occurred during the infusion of activated PC concentrate (twice weekly, up to 68 days after birth). The PC activity levels gradually increased to the standard value for age by 9 months of age. The present case showed that neonatal PC deficiency without a PROC mutation caused an intracranial hemorrhage before a slow increase in PC activity.